Correction: Novel Pyrrolo[3,2-*d*]Pyrimidine Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism with Broad-spectrum Antitumor Efficacy

Aamod S. Dekhne, Khushbu Shah, Gregory S. Ducker, Jade M. Katinas, Jennifer Wong-Roushar, Md. Junayed Nayeen, Arpit Doshi, Changwen Ning, Xun Bao, Josephine Frühauf, Jenney Liu, Adrianne Wallace-Povirk, Carrie O'Connor, Sijana H. Dzinic, Kathryn White, Juiwanna Kushner, Seongho Kim, Maik Hüttemann, Lisa Polin, Joshua D. Rabinowitz, Jing Li, Zhanjun Hou, Charles E. Dann III, Aleem Gangjee, and Larry H. Matherly

Following publication of the original version of this article (1), a resynthesis and reevaluation of a fresh lot of our lead compound AGF347 afforded improved *in vitro* biological activity from that originally published. Examination of the original sample of AGF347 used for the *in vitro* enzyme assays via LC/MS indicated 65% purity at the time these experiments were performed. The origin of the impurity (e.g., contamination or degradation) is unknown. Data collected for serine hydroxymethyl transferase (SHMT) 1 and SHMT2 inhibition assays were impacted by the impure sample such that the original reported Ki values of 2.91 μmol/L (±0.59 SD) for SHMT1 and 2.19 μmol/L (±0.23) for SHMT2 decreased to 1.25 μmol/L (±0.43) for SHMT1 and 0.45 μmol/L (±0.19) for SHMT2 when assays were performed with a separate lot of AGF347 measured at > 98% purity. As all of the other *in vitro* and *in vivo* experiments described in the manuscript used AGF347 at >98% purity, these results are correct as originally reported.

Reference

1. Dekhne AS, Shah K, Ducker GS, Katinas JM, Wong-Roushar J, Nayeen MJ, et al. Novel Pyrrolo[3,2-d]pyrimidine compounds target mitochondrial and cytosolic one-carbon metabolism with broad-spectrum antitumor efficacy. Mol Cancer Ther 2019;18:1787–99.

Published first January 5, 2023.
Mol Cancer Ther 2023;22:287
doi: 10.1158/1535-7163.MCT-22-0766